Clinical Trial Update: Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of Inlexisertib (DCC-3116) in patients with RAS/MAPK pathway mutant solid tumors, including Non-Small Cell Lung Cancer, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumor

Drugs mentioned

• Inlexistertib (DCC-3116)

Snippet

Sponsor: Deciphera Pharmaceuticals, LLC | Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 | Status: TERMINATED